Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AMG 404 Monotherapy in Advanced Solid Tumors (Japan)
jRCT2080224822Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of zeluvalimab in Nonhematologic neoplasms, melanoma, small cell lung cancer (SCLC) and 16 more, sponsored by Amgen. Primary endpoints: Safety and tolerability of AMG 404, Pharmacokinetics of AMG 404 and 2 more. Started Aug 2019; status: completed.
02
Drugs
zeluvalimab
03
Conditions
Nonhematologic neoplasmsmelanomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080224822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224822.